title: MiR-339-5p regulates the growth, colony formation and metastasis of colorectal cancer cells by targeting PRL-1.
abstract: MicroRNAs (miRNAs) have been suggested to play a vital role in regulate tumor progression and invasion. However, the expression of miR-339-5p in colorectal cancer and its effects are not known. Here, we report that miR-339-5p is a tumor suppressor by regulating expression of PRL-1. In this study, we showed that downregulated miR-339-5p levels in colorectal cancer tissues and highly invasive CRC cell lines. Furthermore, enhancing the expression of miR-339-5p inhibited CRC cell growth, migration and invasion in vitro and suppressed tumor growth in vivo. We then screened and identified a novel miR-339-5p target, phosphatases of regenerating liver-1 1 (PRL-1), and it was further confirmed by luciferase assay. Overexpression of miR-339-5p would also reduce the expression of PRL-1 mRNA and protein. The reduced PRL-1 expression was associated with low expression of phosphorylated-extracellular signal-regulated kinase1/2 (p-ERK1/2). Conversely, reduction of miR-339-5p by inhibitors in cells stimulated these phenotypes. In conclusion, our results demonstrate that miR-339-5p functions as a tumor suppressor and plays a role in inhibiting growth and metastasis of CRC cells through targeting PRL-1 and regulating p-ERK1/2 .These findings suggest that miR-339-5p may be useful as a new potential therapeutic target for CRC.
authors.affiliation: Department of Pathology and Key Laboratory of Molecule Tumor Pathology of Guangdong Province, Southern Medical University, Guangzhou, Guangdong, China.
authors.forename: Chang
authors.initials: C
authors.lastname: Zhou
authors.forename: Guobing
authors.initials: G
authors.lastname: Liu
authors.forename: Lijing
authors.initials: L
authors.lastname: Wang
authors.forename: Yanxia
authors.initials: Y
authors.lastname: Lu
authors.forename: Li
authors.initials: L
authors.lastname: Yuan
authors.forename: Lin
authors.initials: L
authors.lastname: Zheng
authors.forename: Fang
authors.initials: F
authors.lastname: Chen
authors.forename: Fanli
authors.initials: F
authors.lastname: Peng
authors.forename: Xuenong
authors.initials: X
authors.lastname: Li
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000627:therapeutic use; D015153:Blotting, Western; D002453:Cell Cycle / Q000187:drug effects / Q000235:genetics; D018797:Cell Cycle Proteins / Q000235:genetics / Q000378:metabolism*; D045744:Cell Line, Tumor; D049109:Cell Proliferation / Q000187:drug effects; D015179:Colorectal Neoplasms / Q000188:drug therapy / Q000235:genetics* / Q000378:metabolism* / Q000628:therapy; D015972:Gene Expression Regulation, Neoplastic / Q000187:drug effects / Q000235:genetics; D006801:Humans; D066298:In Vitro Techniques; D008565:Membrane Proteins / Q000235:genetics / Q000378:metabolism*; D051379:Mice; D035683:MicroRNAs / Q000037:antagonists & inhibitors / Q000235:genetics*; D017027:Protein Tyrosine Phosphatases / Q000235:genetics / Q000378:metabolism*; D023041:Xenograft Model Antitumor Assays
chemical_list: D000970:Antineoplastic Agents; D018797:Cell Cycle Proteins; C543820:MIRN339 microRNA, human; D008565:Membrane Proteins; D035683:MicroRNAs; C490198:PTP4A1 protein, human; D017027:Protein Tyrosine Phosphatases